Why Moderna Stock Climbed Today

Shares of Moderna (NASDAQ: MRNA) rose 4.9% on Monday, after the biotechnology company said it began a study of an experimental COVID-19 vaccine with less restrictive storage requirements.

Moderna dosed the first participants in its phase 1 trial of mRNA-1283, the biotech's refrigerator-stable COVID-19 vaccine candidate. Should it prove both safe and effective, the new vaccine would be easier to transfer, store, and administer, according to CEO Stephane Bancel. That could make it particularly compelling for distribution in markets with less advanced healthcare infrastructure.

Investors bid up Moderna's stock price on Monday. Image source: Getty Images.

Continue reading

Source Fool.com